AML 3.0 by IDMERIT is redefining what modern anti money laundering software looks like - faster screening, smarter monitoring ...
The study focuses on patients unlikely to benefit from azacitidine/venetoclax or showing early resistance. ・SLS009 showed ...
Stocktwits on MSN
SLS stock rallies ahead of AML trial readout — 'Pharma Bro' Martin Shkreli says he's still 'very bearish,' predicts drug will fail
The debate centers on Sellas’ Phase 3 Regal trial, which is testing its immunotherapy Galinpepimut-S (GPS) as a maintenance ...
Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS’ Predictive ...
The rule is already prompting operational changes, new workflows and questions from buyers and sellers first encountering the requirements.
London, UK, March 4th, 2026, FinanceWireAML Union today announced the implementation of enhanced internal compliance ...
New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.
Strategic partnership combines FinScan’s real-time data quality and screening technology with Nexus AML’s expert-led ...
Diligent AI is developing autonomous AI analysts to automate financial crime compliance, aiming to reduce manual workload and ...
South Korea's Bithumb faces a six-month suspension for AML violations, impacting new user transactions amid increased regulatory scrutiny.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results